Clinical Trial Update: Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pasireotide LAR for efficacy and safety in patients with clinically non-functioning pituitary adenoma has completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-functioning Pituitary Adenoma

Drugs mentioned

• Pasireotide LAR (pasireotide)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-functioning Pituitary Adenoma | Phase 2 | Status: COMPLETED | Results posted: 2019-04-26